[Corrigendum] Cripto ‑1 promotes epithelial‑mesenchymal transition in prostate cancer via Wnt/β‑catenin signaling
Oncol Rep. 2024 Jun;51(6):75. doi: 10.3892/or.2024.8734. Epub 2024 Apr 19.ABSTRACTFollowing the publication of the above article, an interested reader drew to the authors' attention that the β‑actin control blots featured in Figs. 5A and 6A appeared to be strikingly similar. Upon examining their original data, the authors have realized that the β‑actin blots for Fig. 5A were inadvertently chosen incorrectly. The corrected version of Fig. 5 is shown opposite. Note that the error made in uploading the incorrect version of this figure did not affect the overall conclusions reported in the paper. All the authors agree wi...
Source: Oncology Reports - April 19, 2024 Category: Cancer & Oncology Authors: Yan Liu Zhenbang Qin Kuo Yang Ranlu Liu Yong Xu Source Type: research
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia
Asia Pac J Clin Oncol. 2024 Apr 19. doi: 10.1111/ajco.14054. Online ahead of print.ABSTRACTStudies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant prostrate cancer have demonstrated increased metastasis-free survival and overall survival following treatment with the next-generation oral anti-androgen apalutamide (in addition to therapies that aim to lower testosterone to castrate levels) or luteinizing hormone-releasing hormone antagonist or surgical castrat...
Source: Clinical Prostate Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Gavin Marx Simon Chowdhury Laurence Krieger Elizabeth Hovey Jeremy Shapiro Ben Tran Thean Hsiang Tan Siobhan Ng Henry H Woo Source Type: research
A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia
Asia Pac J Clin Oncol. 2024 Apr 19. doi: 10.1111/ajco.14054. Online ahead of print.ABSTRACTStudies of patients with castrate-resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on computed tomography or bone scan non-metastatic castrate-resistant prostrate cancer have demonstrated increased metastasis-free survival and overall survival following treatment with the next-generation oral anti-androgen apalutamide (in addition to therapies that aim to lower testosterone to castrate levels) or luteinizing hormone-releasing hormone antagonist or surgical castrat...
Source: Clinical Prostate Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Gavin Marx Simon Chowdhury Laurence Krieger Elizabeth Hovey Jeremy Shapiro Ben Tran Thean Hsiang Tan Siobhan Ng Henry H Woo Source Type: research
Advancing Precision Oncology with Artificial Intelligence: Ushering in the ArteraAI Prostate Test
Due to the negative effects of excessive and inadequate treatment, prostate cancer (PCa) represents the most common cause of cancer-related disability and the leading cause of cancer-related mortality in men.1,2 As such designing treatment regimens for PCa patients is complex. Optimal therapy involves assessing overall health, specific characteristics of their cancer, side effects of treatments, future disease progression, as well as data from clinical trials involving patients with similar diseases. (Source: Urology)
Source: Urology - April 19, 2024 Category: Urology & Nephrology Authors: Salil S. Ghamande, Joseph K. Cline, Rashid K. Sayyid, Zachary Klaassen Source Type: research
Editorial Comment on "Major Complications and Adverse Events Related to use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy"
We read with interest the recent Urology article from Millot et al.1 assessing major complications and adverse events (AEs) related to SpaceOAR hydrogel for prostate cancer (PCa) radiotherapy. There are several sobering findings in this study of the Manufacturer and User Facility Device Experience (MAUDE) database related to SpaceOAR complications – among 990 reported events, there were 350 (35%) patient injuries, 91 (9%) abscesses and fistulas, 5 (0.5%) mortalities, and 123 (12%) Common Terminology Criteria for Adverse Events (CTCAE) grade 3+ AEs. (Source: Urology)
Source: Urology - April 19, 2024 Category: Urology & Nephrology Authors: Zachary Klaassen, J. Kyle Cline, Rashid K. Sayyid Source Type: research
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
CONCLUSIONS AND RELEVANCE: In this study, a new 18-gene PCa test had higher diagnostic accuracy for high-grade PCa relative to existing biomarker tests. Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers. These data support use of this new PCa biomarker test in patients with elevated PSA levels to reduce the potential harms of PCa screening while preserving its long-term benefits.PMID:38635241 | DOI:10.1001/jamaoncol.2024.0455 (Source: Ann Oncol)
Source: Ann Oncol - April 18, 2024 Category: Cancer & Oncology Authors: Jeffrey J Tosoian Yuping Zhang Lanbo Xiao Cassie Xie Nathan L Samora Yashar S Niknafs Zoey Chopra Javed Siddiqui Heng Zheng Grace Herron Neil Vaishampayan Hunter S Robinson Kumaran Arivoli Bruce J Trock Ashley E Ross Todd M Morgan Ganesh S Palapattu Simpa Source Type: research
Recent Updates on Applications of Artificial Intelligence for Nuclear Medicine Professionals: Prostate Cancer and PET/CT
Nucl Med Mol Imaging. 2024 May;58(3):97-100. doi: 10.1007/s13139-024-00856-3. Epub 2024 Feb 24.NO ABSTRACTPMID:38633291 | PMC:PMC11018562 | DOI:10.1007/s13139-024-00856-3 (Source: Molecular Medicine)
Source: Molecular Medicine - April 18, 2024 Category: Molecular Biology Authors: Ki-Seong Park Source Type: research
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ < sup > 177 < /sup > Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
CONCLUSION: We successfully implemented same-day post-therapy SPECT/CT after [177Lu]Lu-PSMA-617 infusions. Quantitation of 1-2 h post-therapy SPECT/CT images is a promising method for assessing treatment response. However, the approach is currently limited by its suboptimal detection of small tumor lesions and the necessity of incorporating a third-cycle SPECT/CT to mitigate the effects of any potential treatment-related flare-up. Further investigation in a larger patient cohort and prospective validation is essential to confirm these findings and to explore the role of SPECT/CT as a potential adjunct to PSMA PET/CT in man...
Source: Molecular Medicine - April 18, 2024 Category: Molecular Biology Authors: Hong Song Maria Isabel Leonio Valentina Ferri Heying Duan Carina Mari Aparici Guido Davidzon Benjamin L Franc Farshad Moradi Jagruti Shah Colin P Bergstrom Alice C Fan Sumit Shah Ali Raza Khaki Sandy Srinivas Andrei Iagaru Source Type: research
Discordant Molecular Imaging Findings with 2-[ < sup > 18 < /sup > F]FDG and [ < sup > 68 < /sup > Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer
We present a case of double primary cancer involving the bladder and prostate, where the prostatic primary showed intense [68Ga]Ga-PSMA uptake with non-avid skeletal and pulmonary metastases, which showed intense 2-[18F]FDG uptake, thus showing discordance due to different clonal origins.PMID:38633286 | PMC:PMC11018560 | DOI:10.1007/s13139-024-00839-4 (Source: Molecular Medicine)
Source: Molecular Medicine - April 18, 2024 Category: Molecular Biology Authors: Aparna Mahalik Jasim Jaleel Sambit Sagar Dikhra Khan Shobhana Raju Rakesh Kumar Source Type: research
Current state of theranostics in metastatic castrate ‐resistant prostate cancer
SummaryProstate cancer remains one of the leading causes of cancer-related death in the world. There have been significant advances in chemotherapy, hormonal therapy and targeted therapy options for patients with castrate-resistant disease. However, these systemic treatments are often associated with unwanted toxicities. Targeted therapy with radiopharmaceuticals has become of key interest to limit systemic toxicity and provides a more precision oncology approach to treatment. Strontium-89, Samarium-153 EDTMP and Radium-223 have been trialled with mixed results. Strontium-89 and Samarium-153 EDTMP have shown benefits in pa...
Source: Journal of Medical Imaging and Radiation Oncology - April 18, 2024 Category: Radiology Authors: Udit Nindra,
Peter Lin,
Therese Becker,
Tara L Roberts,
Wei Chua Tags: Medical Imaging —Review Article Source Type: research
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
ConclusionWe successfully implemented same-day post-therapy SPECT/CT after [177Lu]Lu-PSMA-617 infusions. Quantitation of 1 –2 h post-therapy SPECT/CT images is a promising method for assessing treatment response. However, the approach is currently limited by its suboptimal detection of small tumor lesions and the necessity of incorporating a third-cycle SPECT/CT to mitigate the effects of any potential treatment-rela ted flare-up. Further investigation in a larger patient cohort and prospective validation is essential to confirm these findings and to explore the role of SPECT/CT as a potential adjunct to PSMA PET/CT in ...
Source: European Journal of Nuclear Medicine and Molecular Imaging - April 18, 2024 Category: Nuclear Medicine Source Type: research
Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy
Androgen deprivation therapy (ADT) is a crucial and effective strategy for prostate cancer, while systemic administration may cause profound side effects on normal tissues. More importantly, the ADT can easily... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - April 18, 2024 Category: Nanotechnology Authors: Yiming Guo, Jicheng Wu, Lefan Chen, Lujie Liu, Tianxiang Bi, Yuanwei Pan, Qian-Fang Meng, Chaoliang Wang, Lang Rao and Qi Li Tags: Research Source Type: research
Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy
ConclusionssRP impacts HRQOL in patients with PCa after RT and FT with no significant differences. Comparison with HRQOL and BRFS of treatment alternatives is paramount to counsel patients for appropriate treatments. (Source: World Journal of Urology)
Source: World Journal of Urology - April 18, 2024 Category: Urology & Nephrology Source Type: research
Aggressive variant prostate cancer with multiple subcutaneous metastases: a case report
AbstractA 71-year-old man with bone metastasis of hormone-sensitive prostate cancer was treated with androgen deprivation therapy and apalutamide. Radium-223 and radiation therapy were administered after it become castration resistant. Although prostate-specific antigen levels remained low, multiple subcutaneous metastases of neuroendocrine prostate cancer were observed. A review of the pre-treatment prostate needle biopsy revealed a small component with features suggestive of neuroendocrine differentiation. Phosphatase and tensine homolog loss and tumor protein p53 overexpression were observed, confirming the diagnosis of...
Source: International Cancer Conference Journal - April 18, 2024 Category: Cancer & Oncology Source Type: research
Design and navigation method of a soft robot for single-port transvesical radical prostatectomy
ConclusionsThe designed soft robot system, due to its soft structure, good flexibility, and accurate navigation, is expected to improve surgical safety and precision, thereby exhibiting significant potential for STRP. (Source: International Journal of Computer Assisted Radiology and Surgery)
Source: International Journal of Computer Assisted Radiology and Surgery - April 18, 2024 Category: Intensive Care Source Type: research
